Effects of "legal X" piperazine analogs on dopamine and serotonin release in rat brain

Annals of the New York Academy of Sciences

Volumn 1025, Issue , 2004, Pages 189-197

  Baumann, Michael H ^a,c   Clark, Robert D ^a   Budzynski, Allison G ^a   Partilla, John S ^a   Blough, Bruce E ^b   Rothman, Richard B ^a  

^a IRP   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

1 (m trifluoromethylphenyl)piperazine (TFMPP); 1 Benzylpiperazine (BZP); 3,4 Methylenedioxymethamphetamine (MDMA); Dopamine (DA); Piperazine analog; Serotonin (5 HT)

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN; BRAIN NERVE CELL; BRAIN SYNAPTOSOME; COMPARATIVE TOXICOLOGY; CONFERENCE PAPER; DIALYSATE; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; RAT; SEROTONIN RELEASE; SEROTONIN UPTAKE;

ANIMALIA;

EID: 10444270218     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1316.024     Document Type: Conference Paper

References (25)

1. GREEN, A.R. et al. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol. Rev. 55: 463-508.
2. VOLLENWEIDER, F.X. et al. 1998. Psychological and cardiovascular effects and short-term sequela of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19: 241-251.
3. LIECHTI, M.E. & F.X. VOLLENWEIDER. 2001. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 16: 589-598.
4. ROTHMAN, R.B. & M.H. BAUMANN. 2002. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 95: 73-88.
5. PARROT, A.C. 2002. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 71: 837-844.
6. DRUG ENFORCEMENT ADMINISTRATION. 2001. Drug intelligence brief. BZP and TFMPP: chemicals used to mimic MDMA's effects. http://www.dea.gov/pubs/intel/ 02005/02005.html
7. DE BOER, D. et al. 2001. Piperazine-like compounds: a new group of designer drugs of abuse on the European market. Forensic Sci. Int. 121: 47-56.
8. DEPARTMENT OF JUSTICE. 2002. Schedules of controlled substances: temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into schedule I. http://www.deadiversion.usdojgov/fed_regs/sched_actions/2002
9. SCHOEFFTER, P. & D. HOYER. 1989. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptors ligands exist? Naunyn-Schmiedebergs Arch. Pharmacol. 339: 675-683.
10. PETTIBONE, D.J. & M. WILLIAMS. 1984. Serotonin-releasing effects of substituted piperazines in vitro. Biochem. Pharmacol. 33: 1531-1535.
11. AUERBACH, S.B., J.J. RUTTER & P.J. JULIANO. 1991. Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology 30: 307-311.
12. JONES, C.N., J.L. HOWARD & S.T. MCBENNETT. 1980. Stimulus properties of antidepressants in the rat. Psychopharmacology 67: 111-118.
13. BYE, C. et al. 1973. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur. J. Clin. Pharmacol. 6: 163-169.
14. ROTHMAN, R.B. et al. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
15. BAUMANN, M.H. et al. 2001. 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion. Neuropsychopharmacology 24: 492-501.
16. 3H]dopamine release from superfused brain slices. Eur. J. Pharmacol. 132: 269-276.
17. 3H-5- hydroxytryptamine. Pharmacol. Biochem. Behav. 38: 505-512.
18. BERGER, U.V., X.F. GU & E.C. AZMITIA. 1992. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-choloroamphetamine, and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215: 153-160.
19. AUERBACH, S.B., N. KAMALAKANNAN & J.J. RUTTER. 1990. TFMPP and RU24969 enhance serotonin release from rat hippocampus. Eur. J. Pharmacol. 190: 51-57.
20. GUDELSKY, G.A. & J.F. NASH. 1996. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66: 243-249.
21. GOUGH, B. et al. 1991. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39: 619-623.
22. NASH, J.F. & J. BRODKIN. 1991. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259: 820-825.
23. RATZENBOECK, E. et al. 2001. Reinforcing effects of MDMA ("ecstasy") in drug-naïve and cocaine-trained rats. Pharmacology 62: 138-144.
24. SCHENK, S. et al. 2003. Development, maintenance, and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169: 21-27.
25. BAUMANN, M.H., J.J. RUTTER & S.B. AUERBACH. 1993. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32: 1381-1386.